InspireMD 收 Nasdaq 警告信 股價連續30日低於1美元面臨除牌風險

false
 0001433607
 
 
 
 
 
 
 
 0001433607
 
 
 2026-07-17
 2026-07-17
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

 

 

 

FORM
8-K

 

 

 

CURRENT
REPORT

Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date
of Report (Date of earliest event reported): July 17, 2026

 

 

 

InspireMD,
Inc.

(Exact
name of registrant as specified in its charter)

 

 

 

 
 Delaware
  
 001-35731
 
  
 26-2123838

 
 (State
 or other jurisdiction

 of
 incorporation)

  
 (Commission

 File
 Number)

  
 (IRS
 Employer

 Identification
 No.)

 
 

 
 6303
 Waterford District Drive, Suite 215

 Miami,
 Florida 33126

  
 33126

 
 (Address
 of principal executive offices)
  
 (Zip
 Code)

 
 

Registrant’s
telephone number, including area code: (888) 776-6804

 

 

(Former
name or former address, if changed since last report.)

 

 

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:

 

 
 ☐
 Written
 communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ☐
 Soliciting
 material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 
  
  

 
 ☐
 Pre-commencement
 communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

Securities
registered pursuant to Section 12(b) of the Act:

 

 
 Title
 of each class
  
 Trading
 Symbol(s)
  
 Name
 of each exchange on which registered

 
 Common
 Stock, $0.0001 par value per share
  
 NSPR
  
 The
 Nasdaq Capital Market

 
 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging
growth company ☐

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

  

 

 

Item
3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On
July 17, 2026, InspireMD, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications
Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum
bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2), which requires listed
securities to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market. The Notice stated that,
based upon the closing bid price of the Company’s common stock for the 30 consecutive business days from June 3, 2026 through July
16, 2026, the Company no longer satisfies the minimum bid price requirement.

 

The
Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on The Nasdaq
Capital Market under the symbol “NSPR.”

 

In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a compliance period of 180 calendar days, or until January
13, 2027, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the closing bid price of the Company’s
common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period. Nasdaq may,
in its discretion, require the Company to satisfy the minimum bid price requirement for a period in excess of ten consecutive business
days before determining that the Company has demonstrated an ability to maintain long-term compliance.

 

If
the Company does not regain compliance by January 13, 2027, the Company may be eligible for an additional 180-calendar-day compliance
period, provided that it satisfies the continued listing requirement for market value of publicly held shares and all other initial listing
standards for The Nasdaq Capital Market, other than the minimum bid price requirement, and provides written notice to Nasdaq of its intention
to cure the deficiency during the second compliance period, including, if necessary, by effecting a reverse stock split. If the Company
is not eligible for an additional compliance period, or otherwise does not appear capable of curing the deficiency, Nasdaq may provide
notice that the Company’s common stock will be subject to delisting. In that event, the Company would have the opportunity to appeal
Nasdaq’s determination to a Nasdaq Hearings Panel.

 

The
Company intends to actively monitor the closing bid price of its common stock and evaluate available options to regain compliance with
the minimum bid price requirement, including, if necessary, effecting a reverse stock split. There can be no assurance that the Company
will regain compliance with Nasdaq Listing Rule 5550(a)(2) during the initial compliance period or any additional compliance period,
or that the Company will otherwise maintain compliance with the other Nasdaq listing requirements.

 

Item
9.01 Financial Statements and Exhibits.

 

(d)
Exhibits.

 

 
 Exhibit
Number
  
 Description

 
 104
  
 Cover
 Page Interactive Data File (embedded within the Inline XBRL document)

 
 

  

  

 

 

SIGNATURES

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

 

 
  
  
 INSPIREMD,
 INC.

 
  
  
  
  

 
 Date:
 July
 23, 2026
 By:
 /s/
 Marvin Slosman

 
  
  
 Name:
 Marvin
 Slosman

 
  
  
 Title:
 Chief
 Executive Officer